This study is a marketing-oriented clinical trial of TQH3906 Capsules. A total of 156 participants are planned to be enrolled, aiming to evaluate the dose-effect relationship of TQH3906 versus placebo in the treatment of active Psoriatic Arthritis (PsA) at Week 12, with the proportion of participants achieving an American College of Rheumatology 20% (ACR20) Improvement Criteria (ACR20) response at Week 12 as the primary endpoint.
Sign a written Informed Consent Form, which must meet the following requirements
Be willing to participate in the study and able to sign the informed consent form;
Be willing and able to complete all study-specific procedures and visits;
PsA trial participant disease characteristics
Presence of non-plaque psoriasis (i.e., guttate, inverse, pustular, erythrodermic, or drug-induced psoriasis) at screening or first dose;
Presence of any other autoimmune disease, such as rheumatoid arthritis, systemic lupus erythematosus, etc.;
Presence of active (i.e., currently symptomatic) fibromyalgia;
Trial participants who are pregnant or breastfeeding;
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Lead sponsor